These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8269588)

  • 61. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC; Wilson PA; Steel GG
    Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio.
    Du L; Fei Z; Song S; Wei N
    Biomed Pharmacother; 2017 Nov; 95():447-452. PubMed ID: 28865364
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
    Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [TBL] [Abstract][Full Text] [Related]  

  • 65. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
    Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
    Ferguson PJ; Currie C; Vincent MD
    Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
    Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
    Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Platinum anticancer drugs. From serendipity to rational design.
    Monneret C
    Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
    Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
    Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma.
    Chen Z; Xu G; Wu D; Wu S; Gong L; Li Z; Luo G; Hu J; Chen J; Huang X; Chen C; Jiang Z; Li X
    Biochem Pharmacol; 2020 Jul; 177():114023. PubMed ID: 32413426
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lobaplatin induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion.
    Li Y; Liu B; Yang F; Yu Y; Zeng A; Ye T; Yin W; Xie Y; Fu Z; Zhao C
    Biomed Pharmacother; 2016 Oct; 83():1239-1246. PubMed ID: 27565846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
    Coley HM; Sarju J; Wagner G
    J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anticancer Mechanism of Lobaplatin as Monotherapy and in Combination with Paclitaxel in Human Gastric Cancer.
    Hua S; Kong X; Chen B; Zhuang W; Sun Q; Yang W; Liu W; Zhang Y
    Curr Mol Pharmacol; 2018; 11(4):316-325. PubMed ID: 30101722
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
    Chen L; Cao H; Yu C; Feng Y
    Fundam Clin Pharmacol; 2018 Oct; 32(5):548-557. PubMed ID: 29733466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.